爱泼斯坦-巴尔病毒血清学状态对成人炎症性肠病患者临床结局的影响
总体血清阳性率为97.4%(95%CI:96.6%-98.2%),平均47.5个月后血清转化率为29.7%(95%CI:16.2-45.9),35岁及以下与35岁以上患者间无差异。作者认为考虑使用硫嘌呤时,任何年龄均应参考EBV血清学状态信息。
要点
- 成人炎症性肠病患者EBV总体血清阳性率为97.4%(95%CI:96.6%-98.2%)。
- 血清阴性患者平均47.5个月后血清转化率为29.7%(95%CI:16.2-45.9),年龄分组间无差异。
- 6例患者发生淋巴瘤,其中3例使用硫嘌呤且EBV与淋巴瘤发生相关。
核心结论
- 少数成人炎症性肠病患者存在原发性EBV感染风险,血清转化及其并发症的风险持续至成年期。
- 作者认为,在考虑对炎症性肠病患者使用硫嘌呤时,任何年龄均应参考EBV血清学状态信息。
主要发现
- EBV总体血清阳性率为97.4%(95%CI:96.6%-98.2%)。
- 血清阴性患者平均47.5个月后血清转化率为29.7%(95%CI:16.2-45.9)。
- 35岁及以下患者与35岁以上患者的血清转化率无差异。
- 一名66岁正在接受硫嘌呤治疗的男性在原发性EBV感染期间发生淋巴瘤和噬血细胞综合征。
- 共有6例患者(1例原发性感染和5例既往EBV感染)发生淋巴瘤;5例淋巴瘤患者中3例使用硫嘌呤且EBV与淋巴瘤发生相关。
临床怎么用
- 作者认为,在考虑对炎症性肠病患者使用硫嘌呤时,任何年龄均应参考EBV血清学状态信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the impact of Epstein-Barr virus (EBV) infection on clinical outcomes in adults with inflammatory bowel disease (IBD). AIM: To evaluate seroprevalence, seroconversion rate and complications associated with EBV infection in an adult IBD cohort attending a tertiary care hospital in Spain between 2006 and 2016. METHODS: EBV serological status was determined. In seronegative patients, the seroconversion rate was evaluated. The complications associated with primary and latent EBV infection are described. RESULTS: One thousand four hundred and eighty-three patients over the age of 17 were included in the study (mean age at EBV serological status determination was 48.3). Overall seroprevalence of EBV was 97.4% (95% CI: 96.6%-98.2%). The seroconversion rate was 29.7% (95% CI: 16.2-45.9) after a mean of 47.5 months. There were no differences in seroconversion rates between patients 35 years or younger and patients older than 35 years. A 66-year-old man, on treatment with thiopurines, developed lymphoma and a hemophagocytic syndrome during a primary EBV infection. Overall, six patients (one with primary infection and five with prior EBV infection) developed lymphoma. In three of five patients with lymphoma and thiopurine use, EBV was associated to the development of lymphoma. CONCLUSIONS: There is a small percentage of adults with IBD at risk of primary EBV infection. The risks of seroconversion and its complications remain through adulthood. Our results suggest that, when considering the use of thiopurines in IBD, the information on EBV serological status should be taken into account at any age.
引用
- de Francisco R, Castaño-García A, Martínez-González S, et al. Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018. PMID: 30095176. doi:10.1111/apt.14933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。